Roche's Xeloda Medicare Part B Reimbursement Raised To 90% Of AWP
This article was originally published in The Pink Sheet Daily
Executive Summary
Centers for Medicare & Medicaid Services raises Xeloda's reimbursement rate from 85% of AWP based on data submitted by Roche. CMS also corrects payment allowance for the company's CellCept.
You may also be interested in...
Xeloda Growth Due To Off-Label Adjuvant Colorectal Cancer Use, Roche Says
The increase in Xeloda prescribing is also “partly due to some change in the reimbursement patterns,” Pharma Strategic Marketing Head Sabbah says. U.S. sales for the first quarter were up 74% to approximately $51 mil.
Xeloda Growth Due To Off-Label Adjuvant Colorectal Cancer Use, Roche Says
The increase in Xeloda prescribing is also “partly due to some change in the reimbursement patterns,” Pharma Strategic Marketing Head Sabbah says. U.S. sales for the first quarter were up 74% to approximately $51 mil.
Medicare Law Causes Roche To Hesitate On Oncology Price Increases
Roche and Genentech were "circumspect" about implementing price increases given the confusion over Medicare reimbursement, Roche Worldwide Pharmaceuticals Head Burns says. European prices for the companies' oncology products drop.